Ph2 study comparing ABBV-400 with Post adjuvant ctDNA and NED
Phase II Clinical Trial
Colorectal Cancer: A Phase 2 Randomized Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) (M24-534)